UHTR

seekingalpha.com/article/...on-good-news-why-i-bought-that-dip
www.unither.com

www.unither.com
financials.morningstar.com/ratios/r.html?t=UTHR
markets.ft.com/research/Markets/Tearsheets/Forecasts?…
www.macroaxis.com/invest/compare/UTHR

Kurzporträt



Logo United Therapeutics Corpor
Develops pharmaceutical products

United Therapeutics Corp. operates as a biotechnology company, which focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

The company operates in two business segments: Pharmaceuticals and Telemedicine.

Its primary product Remodulin is used for the treatment of pulmonary arterial hypertension and the company also develops glycol-biological antiviral agents for the treatment of infectious diseases, such as Hepatitis C. United Therapeutics was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

de.4-traders.com/UNITED-THERAPEUTICS-CORPO-11262/fundamentals/

www.analystratings.com/articles/...a-buy-rating-from-wedbush/

www.analystratings.com/articles/...ed-its-third-buy-in-a-row/

• Dr. Reddy's kündigt die Einführung der Treprostinil Injektion an, einer therapeutischen äquivalenten generischen Version von Remodulin (Treprostinil) Injektion
  

www.sec.gov/Archives/edgar/data/1135951/...drr0473_ex99-1.htm
Remodulin ist UTHR's zweitstärkstes Produkt, gemessen am Umsatz von 500 Mio. $ in 2022